Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Keep Hope Alive for Everyone Living with CMT
…CMTA has invested over $17 million in CMTA-STAR research since 2008, making us the largest chartable funder of CMT research globally. But our work isn’t done: Our strategy outlines investments…
NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
…the ongoing research will lead to significant advancements in treating CMT and improving the lives of those affected by this condition. Register with Patients as Partners in Research Today CMTA…
Fall 2024 CMTA Report
…in Research platform. IMPACT: A potential treatment for CMT2C. RESEARCH UPDATES At the core of CMTA’s mission, CMTA-STAR (Strategy to Accelerate Research) accelerates pioneering research to develop treatments and ultimately…
2022 Annual Report_spreads
…research, community support and stewardship of funds. Since the CMTA instituted its Strategy to Accelerate Research (STAR) in 2008, the field of CMT research has grown by leaps and bounds….
CMTAreportspring24FINALwebSPREADS
…STAR (Strategy to Accelerate Research), our premier research initiative, as well as important community initiatives like Camp Footprint, Patient/Research Conferences, and educational programs. All of these programs require steady, reliable…
CMTAWinter2023webspreads
…The CMTA Patient & Research Summit covered all my interests. I felt honored to be in the presence of the top researchers and scientists spearheading the research for a cure…
DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR) and led by CMTA-STAR Advisory Board member Mario Saporta, MD, PhD,…
CMTA Alliance Partner, NMD Pharma, Announces Encouraging Data with Implications for CMT
…Forsey, Ph.D., CMTA chief research officer. “NMD Pharma’s pioneering research not only sheds light on novel therapeutic avenues but also underscores the interconnectedness of neuromuscular disorders. We eagerly anticipate the…
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C
…Research Today Not yet registered with Patients as Partners in Research? Click the button below to register today! Registering ensures you are the first in line for any CMT research…
2023 CMTA-STAR Celebrating our Collective Achievements
Significant Research Investment Made in 2023: We are excited to share that in 2023, the CMTA has ongoing and committed investments of $5,000,00 in research dedicated to finding effective treatments…